The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Onpattro Market?
Historical growth can be linked to progress in RNA-centric drug development, a greater incidence of hATTR amyloidosis diagnoses, the granting of regulatory approvals for gene-silencing treatments, an expansion in specialty infusion center availability, and the clinical confirmation of patisiran’s effectiveness.
Future growth is expected to be driven by the expanding scope of next-generation RNA therapeutics, a rise in investments targeting rare disease pipelines, an increasing emphasis on personalized medicine, the emergence of subcutaneous delivery options, and the increasing uptake of genetic screening initiatives.
Key trends for the upcoming period are characterized by a growing acceptance of RNA interference therapies, an elevated focus on treating rare genetic diseases, the broadening application of precision gene silencing methods, better clinical results in amyloidosis management, and the increasing incorporation of advanced infusion treatments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp
What Market Drivers Are Helping Shape The Onpattro Market Expansion?
The increasing incidence of hereditary transthyretin-mediated amyloidosis is anticipated to drive the expansion of the onpattro market in the future. This condition, also known as hATTR, is an uncommon genetic illness characterized by the formation of detrimental deposits from mutated TTR proteins, impacting both the nervous system and cardiac function. The growing occurrence of hATTR is fueled by improved diagnostic methods, widespread genetic screening, and enhanced public understanding, leading to the identification of more patients. Onpattro serves as a treatment for hereditary transthyretin-mediated amyloidosis by inhibiting the transthyretin (TTR) gene, thereby decreasing amyloid protein synthesis and mitigating organ harm. For example, data from February 2024, sourced from Verywell Health, a U.S. health information platform, indicates that hereditary transthyretin-mediated amyloidosis impacts 5,500–38,500 individuals worldwide. In the U.S., estimates for hereditary transthyretin-mediated amyloidosis with polyneuropathy range from 104 to 3,847 cases, underscoring substantial underdiagnosis. Consequently, the increasing prevalence of hereditary transthyretin-mediated amyloidosis is a key factor propelling the expansion of the onpattro market.
Which Segment-Based Categories Are Covered In The Onpattro Market?
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
Which Trends Are Influencing The Expansion Of The Onpattro Market?
A significant trend within the onpattro market revolves around broadening the drug’s approved indications through additional supplemental drug applications, with the objective of maximizing its market potential and addressing a wider array of patient needs. Supplemental drug applications typically aim to extend a drug’s sanctioned uses, such as targeting new conditions, patient demographics, or formulations, to enhance its therapeutic scope and market viability. For instance, in February 2023, Alnylam Pharmaceuticals, a pharmaceutical company based in the US, announced the acceptance of a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran). This treatment is intended for cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO acts as an RNA interference (RNAi) therapeutic specifically engineered to target the transthyretin (TTR) protein, which can accumulate abnormally in individuals with ATTR amyloidosis, resulting in severe complications, including cardiomyopathy. The drug first received approval in 2018 for managing polyneuropathy connected to hereditary ATTR amyloidosis. The recent sNDA submission drew upon data from the Phase III APOLLO-B study, which demonstrated that patisiran substantially improved both the functional capacity and quality of life in patients suffering from cardiomyopathy when compared to a placebo.
Which Companies Form The Competitive Landscape Of The Onpattro Market?
Major companies operating in the onpattro market are Alnylam Pharmaceuticals Inc.
Access The Complete Onpattro Market Report:
https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report
Which Region Has The Strongest Presence In The Onpattro Market?
North America was the largest region in the onpattro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model